trial results to look out for
.Ongoing randomized phase III trials in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer.
Clinical trial NEFERTT (N = 1200) First-line metastatic BO22589 (N = 1092) First-line metastatic EMILIA (N = 580) Locally advanced or metastatic PHEREXA (N = 450) Second-line after trastuzumab BOLERO-1 (N = 717) First-line metastatic BOLERO-3 (N = 572) Resistant to trastuzumab Study arms Neratinib + Paclitaxel Trastuzumab + Paclitaxel Herceptin + taxane T-DM1 T-DM1 + pertuzumab T-DM1 Capecitabine + lapatinib Docetaxel + trastuzumab + pertuzumab Capecitabine + trastuzumab Capecitabine + trastuzumab + Pertuzumab Pertuzumab + trastuzumab Pertuzumab + trastuzumab + everolimus Vinorelbine + trastuzumab Vinorelbine + trastuzumab + everolimus Trial endpoint/ WHEN Data expected: PFS, OS 2012 PFS 2012 PFS, OS, ORR 2013 PFS, TTP, TTF, ORR, CBR 2015 PFS, OS, ORR, CBR, TTR 2012 PFS, OS, ORR, CBR 2012 CBR, clinical benefit rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure; TTP, time to progression; TTR, time in treatment range. |
Re: trial results to look out for
Bless you Lani, as usual!!
|
Re: trial results to look out for
Lani
thank you for keeping us so very informed. Have you heard anything about the Hera trial, whether 2 years is better than on year of Herceptin? thank you :) |
Re: trial results to look out for
nothing on the 2yr vs 1 yr hera results yet
|
Re: trial results to look out for
Thanks Lani
Just saw onc yesterday and we were discussing it again and when we thought those results were going to be reported on. I appreciate your diligence. |
Re: trial results to look out for
Lani
Do you think they will ever publish the one year versus two year HERA study results? |
All times are GMT -7. The time now is 01:44 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021